Irish Companies in India: Tech, Pharma & Low-Tax Structure Optimization

Why Irish Companies Are Expanding Rapidly in India

The India-Ireland DTAA caps withholding tax on dividends, interest, royalties, and technical service fees at a flat 10% — half the 20% domestic rate — making it one of Europe's most favorable tax treaties for structuring cross-border payments between the two countries. Two-way trade already exceeds EUR 16 billion annually, with services trade alone surpassing EUR 8.8 billion in 2024, as Ireland's technology and pharmaceutical multinationals tap India's engineering talent, cost arbitrage, and market access.

Over 100 Irish-connected companies, including Accenture and Medtronic, now operate in India, spanning foreign direct investment in technology services, pharmaceutical manufacturing, medical devices, and financial services. The relationship accelerated following Brexit, as Ireland became the primary English-speaking EU gateway for companies seeking both European market access and Indian operational scale.

For Irish companies considering Indian market entry, understanding the structural options, tax treaty benefits, and sector-specific regulatory frameworks is essential — the wrong structure can result in double taxation, transfer pricing disputes, and regulatory non-compliance that erodes the cost advantages India offers.

The Ireland-India Trade and Investment Landscape

Bilateral Trade Metrics

India's total goods trade with Ireland reached USD 6.4 billion in FY 2023-24, with India importing USD 5.6 billion worth of goods from Ireland, primarily pharmaceutical intermediates, medical devices, and technology components. India's exports to Ireland stood at USD 702.7 million, comprising organic chemicals, machinery, and IT services.

The services trade dwarfs goods trade. Ireland's services exports to India reached EUR 8,882 million in 2024, reflecting the deep integration of Irish-headquartered tech and pharma companies with their Indian operations. The Joint Economic Commission established during External Affairs Minister Jaishankar's March 2025 visit to Dublin is expected to further accelerate bilateral investment.

Key Irish Companies in India

Several major Irish-incorporated multinationals maintain significant Indian operations:

• Accenture (Dublin-headquartered): Over 300,000 employees across India with offices in Bengaluru, Mumbai, Gurugram, Hyderabad, Pune, Chennai, Noida, Coimbatore, Indore, Jaipur, and Kolkata. India is Accenture's largest delivery center globally.
• Medtronic (Dublin-headquartered): Operates manufacturing, R&D, and commercial operations in India, covering medical devices and surgical technologies.
• Kerry Group (Tralee-headquartered): Food technology and nutrition solutions provider with Indian manufacturing facilities.
• Kingspan Group (Kingscourt-headquartered): Building materials and insulation manufacturer with Indian operations.

Entity Structuring Options for Irish Companies

Irish companies entering India must choose between several legal structures, each with distinct regulatory, tax, and operational implications. The choice fundamentally affects repatriation flexibility, transfer pricing complexity, and long-term exit options.

Wholly Owned Subsidiary (Private Limited Company)

The wholly owned subsidiary is the preferred structure for most Irish companies establishing significant Indian operations. Incorporated as an Indian Private Limited Company under the Companies Act, 2013, it provides:

• 100% ownership under the automatic route for most tech and pharma activities
• Limited liability protection separating Irish parent from Indian obligations
• Full profit repatriation rights after Indian taxes
• Ability to own Indian real estate and intellectual property
• Access to the concessional 22% corporate tax rate (plus surcharge and cess)

Registration requires filing SPICe+ with the MCA, obtaining a Digital Signature Certificate for at least two directors, and appointing a resident director who has stayed in India for at least 182 days in the financial year.

Branch Office

A branch office is suitable for Irish companies that want to test the Indian market without incorporating a separate entity. Branch offices can engage in export/import, consultancy, IT services, and technical support. However, they face the 35% corporate tax rate applicable to foreign companies (reduced from 40% effective April 2024) and cannot undertake direct manufacturing.

Liaison Office

A liaison office functions as a communication channel between the Irish parent and Indian customers. It cannot earn revenue in India and is funded entirely by remittances from Ireland. Liaison offices are useful for market research and relationship-building but have limited utility for tech and pharma companies seeking operational scale.

For a detailed comparison, see our guide on branch office vs subsidiary structures and Irish Ltd vs Indian Pvt Ltd.

Tech Sector: How Irish Tech Companies Structure Indian Operations

Ireland's position as the European tech hub means that many of the world's largest technology companies are technically Irish-incorporated entities with massive Indian delivery centers. This creates unique structuring opportunities and compliance requirements.

Global Capability Centers (GCCs)

The GCC model dominates Irish tech companies' India strategy. These centers function as wholly owned subsidiaries providing engineering, product development, customer support, and business process services to the Irish parent and its global operations. Key considerations include:

• Transfer pricing structure: Most Irish tech GCCs operate on a cost-plus model. The arm's-length markup is not fixed by statute — it must be benchmarked annually against comparable Indian IT services companies and supported by contemporaneous documentation.
• IP ownership: Intellectual property developed in Indian GCCs should be governed by clear IP assignment agreements. The transfer pricing implications of IP migration between Ireland and India can be substantial under the OECD BEPS framework.
• Employee scale: India is the single largest country headcount for several Irish-incorporated multinationals — Accenture alone employs over 300,000 people across its Indian offices.

IT Services and Software Development

100% FDI is permitted under the automatic route for IT and ITeS activities. Irish tech companies entering India for software development, cloud services, AI/ML, and cybersecurity face no sectoral caps or government approval requirements. The FC-GPR filing with the RBI must be completed within 30 days of share allotment.

Pharma Sector: Regulatory and Tax Considerations

The pharma connection between Ireland and India is particularly significant. Ireland hosts operations of most of the world's largest pharmaceutical companies and is one of Europe's largest pharmaceutical exporters. India, in turn, is the world's largest producer of generic medicines by volume. This complementarity creates natural partnerships.

FDI in Pharmaceutical Manufacturing

100% FDI is permitted under the automatic route for greenfield pharmaceutical projects. For brownfield investments (acquisitions of existing Indian pharma companies), 100% FDI is allowed but investments beyond 74% require government approval. Irish pharma companies must also comply with:

• CDSCO (Central Drugs Standard Control Organisation) licensing requirements
• State-level drug manufacturing licenses
• WHO-GMP certification for export-oriented units
• Environmental clearances from state pollution control boards

Contract Research and Development

Irish pharmaceutical companies increasingly use Indian contract research organizations (CROs) for clinical trials, bioequivalence studies, and drug formulation development. This creates permanent establishment risks if the Indian CRO is treated as a dependent agent rather than an independent contractor. Proper structuring under Article 5 of the India-Ireland DTAA is critical.

Medical Devices and MedTech

India's medical device market is projected to reach USD 50 billion by 2030, creating significant opportunities for Irish medtech companies. 100% FDI is permitted under the automatic route for medical device manufacturing. The BIS (Bureau of Indian Standards) certification and CDSCO registration requirements apply, and Irish companies should factor in 6-12 months for regulatory approvals.

India-Ireland DTAA: Tax Treaty Benefits

The India-Ireland DTAA, signed on 6 November 2000, in force from 26 December 2001 and effective in India for fiscal years beginning on or after 1 April 2002, is one of the more favorable European tax treaties for companies operating across both jurisdictions. It follows the credit method for eliminating double taxation.

Key Withholding Tax Rates

The uniform 10% withholding rate across dividends, interest, royalties, and technical service fees makes the India-Ireland DTAA one of the most attractive treaties for cross-border payments. Under Article 11(3), interest derived and beneficially owned by the Irish Government, a statutory body or the Central Bank of Ireland — or paid on a loan or credit extended, guaranteed or insured by them — is fully exempt from Indian withholding tax; ordinary Irish commercial bank lending pays the 10% treaty rate.

To claim treaty benefits, the Irish company must obtain a Tax Residency Certificate from the Irish Revenue Commissioners — its own tax authority. A TRC for an Irish resident is never issued by the Indian Income Tax Department, and Form 42 (formerly Form 10FA) is not the route to one: that form is an Indian resident's application to an Indian Assessing Officer. Alongside the Irish TRC, the Irish company files Form 41 (formerly Form 10F) electronically on the Indian income tax portal; treaty relief at source is available only once that declaration is on record. The Indian payer then files Form 145 (formerly Form 15CA) before remitting payments, adding a Form 146 (formerly Form 15CB) certificate only for Part C — a taxable remittance above INR 5 lakh in the financial year that is not covered by an Assessing Officer's certificate, certifying the applicable DTAA rate and the payee's eligibility.

Permanent Establishment Considerations

Irish companies with employees or fixed places of business in India risk creating a permanent establishment (PE) under Article 5 of the DTAA. A PE triggers Indian corporate tax liability on profits attributable to the Indian establishment. Common PE risks for Irish tech and pharma companies include:

• Employees negotiating or concluding contracts in India on behalf of the Irish entity
• A fixed place of business in India — an office or dedicated co-working space at the Irish company's disposal (no minimum duration applies)
• Dependent agents with authority to bind the Irish company
• Construction, installation or assembly projects (including supervisory activities) lasting more than six months under Article 5(3)

For detailed guidance on DTAA planning for foreign companies, see our comprehensive guide.

Corporate Tax Optimization Strategies

Choosing the Right Tax Regime

Indian subsidiaries of Irish companies can choose between several corporate tax regimes:

• Standard rate: 22% (plus 10% surcharge and 4% cess, effective rate ~25.17%) under section 200 read with section 205(1) of the Income-tax Act, 2025 (section 115BAA of the Income-tax Act, 1961), available if the company foregoes certain deductions and exemptions
• New manufacturing rate: 15% (plus 10% surcharge and 4% cess, effective rate ~17.16%) under section 201 read with section 205(2) of the Income-tax Act, 2025 (section 115BAB of the Income-tax Act, 1961), for companies incorporated after October 1, 2019 that commenced manufacturing on or before March 31, 2024
• Foreign company rate: 35% (reduced from 40% effective April 2024, plus applicable surcharge and cess) for branch offices and other non-incorporated structures

The 22% concessional rate typically delivers the best effective tax rate for Irish companies operating through Indian subsidiaries, as it eliminates the need for complex tax holiday claims while offering a globally competitive rate.

Transfer Pricing Compliance

Irish-Indian intercompany transactions are subject to Indian transfer pricing regulations under sections 161 to 173 of the Income-tax Act, 2025 (sections 92 to 92F of the Income-tax Act, 1961). Key compliance requirements include:

• Annual transfer pricing documentation (Form 48 (formerly Form 3CEB) due by October 31 — one month before the November 30 return due date; from tax year 2026-27 it is replaced by Form 48 under the Income-tax Rules, 2026)
• Country-by-Country Reporting for Irish groups with consolidated revenue exceeding EUR 750 million
• Benchmarking studies using the Transactional Net Margin Method (TNMM) or Comparable Uncontrolled Price (CUP) method
• Advance Pricing Agreements (APAs) available for 5-year certainty on pricing methodology

Irish tech companies using cost-plus transfer pricing for their Indian GCCs should set the markup from a current benchmarking study of comparable Indian IT services companies rather than from a rule of thumb; Indian transfer pricing officers test the declared margin against that comparable set, and an unsupported markup is a common trigger for adjustment.

Dividend Repatriation Strategy

Dividends from Indian subsidiaries to Irish parent companies are subject to 10% withholding tax under the DTAA (compared to 20% without treaty benefits). The Irish parent can claim a foreign tax credit in Ireland for the Indian withholding tax paid, effectively reducing the overall tax burden. For a deeper analysis of repatriation structures, see our guide on funding Indian subsidiaries.

EU-India FTA: Impact on Irish Companies

The EU-India Free Trade Agreement, concluded on January 27, 2026, represents a transformative development for Irish companies operating in India. As an EU member state, Ireland benefits directly from the FTA's provisions.

Key FTA Benefits for Irish Companies

• Tariff reductions: Phased elimination of customs duties on pharmaceutical intermediates, medical devices, and technology equipment imported from the EU
• Services market access: Enhanced access for Irish IT and professional services firms, including provisions for temporary movement of business professionals
• Digital trade chapter: Provisions facilitating cross-border data flows, which benefit Irish tech companies with Indian data processing centers
• Intellectual property protections: Strengthened IP enforcement mechanisms relevant to Irish pharma and tech companies

The FTA is not yet in force. It requires approval by the Council of the European Union, consent of the European Parliament, and ratification by the Indian Union Council of Ministers. Implementation is expected in phases, with longer transition periods for sensitive sectors; the staging schedules are set out in the agreement's tariff annexes.

For where the EU-India FTA sits among India's other trade agreements and their entry-into-force status, see our India FTA tracker for 2026.

Compliance Framework for Irish Companies in India

Annual Filing Requirements

An Indian subsidiary of an Irish company faces the following annual compliance obligations:

• MCA filings: Annual return (Form MGT-7) and financial statements (Form AOC-4) due within 60 and 30 days of the AGM respectively
• Tax filings: Income tax return due November 30 for companies with transfer pricing obligations (October 31 for other companies under tax audit), advance tax in quarterly installments (June 15, September 15, December 15, March 15)
• RBI/FEMA reporting: FC-GPR within 30 days of share allotment, FLA return by July 15 annually, ECB returns as applicable
• GST compliance: Monthly GSTR-1 and GSTR-3B filings, annual return in GSTR-9
• Transfer pricing: Form 48 due October 31, maintain contemporaneous documentation

FEMA Compliance

FEMA governs all foreign exchange transactions between the Irish parent and Indian subsidiary. Key requirements include pricing of shares at or above fair market value (determined by internationally accepted pricing methodology for unlisted companies), reporting of all inbound remittances through AD Category-I banks, and maintaining proper documentation for all cross-border payments.

SEZ and Special Incentive Zones for Irish Companies

Indian Special Economic Zones (SEZs) offer additional benefits for Irish companies establishing manufacturing or IT operations. Key SEZ advantages include customs duty exemption on imports of capital goods and raw materials, simplified customs procedures with self-certification, and exemption from GST on procurement of goods and services for authorized operations. The Section 10AA income tax exemption (100% of export profits for the first five years, 50% for the next five) is closed to new units — it applies only to SEZ units that commenced operations on or before 31 March 2021 — so Irish companies establishing new SEZ operations today cannot claim this holiday.

For Irish pharma companies, Genome Valley in Hyderabad and the Pharma SEZ in Visakhapatnam offer specialized infrastructure including pre-built laboratory spaces, common effluent treatment plants, and proximity to contract research organizations. For Irish tech companies, IT SEZs in Bengaluru (ITPB, Embassy Manyata, RMZ Ecoworld), Hyderabad (HITEC City), and Pune (Hinjewadi) provide grade-A office space with built-in redundant power and fiber connectivity.

The Indian government has proposed a Development of Enterprise and Service Hubs (DESH) Bill to replace the traditional SEZ framework, though it has not been enacted. Irish companies setting up new operations should track the proposal alongside existing SEZ benefits to determine the optimal location and structure.

Production Linked Incentive (PLI) Schemes Relevant to Irish Companies

Irish pharmaceutical companies can access PLI incentives in three categories: bulk drugs (41 identified products with incentives of 10% on incremental sales), medical devices (incentives of 5% on incremental sales for 4 target segments), and pharmaceutical products (incentives of 3-10% on incremental sales for 35 identified products). Irish medtech companies manufacturing in India can leverage these schemes to offset initial capital expenditure and achieve cost-competitive production for both domestic and export markets.

For Irish tech companies, the PLI scheme for IT hardware offers incentives of 1-4% on net incremental sales for manufacturing laptops, tablets, servers, and all-in-one PCs in India. While most Irish tech companies are services-oriented, those with hardware manufacturing ambitions can benefit from these targeted production incentives.

Key Takeaways

• The India-Ireland DTAA offers a uniform 10% withholding rate on dividends, interest, royalties, and technical service fees, making it one of Europe's most favorable tax treaties for Indian operations
• Irish tech companies should structure Indian GCCs as wholly owned subsidiaries on a cost-plus transfer pricing model, with the markup set by an annual benchmarking study rather than a rule of thumb
• 100% FDI is permitted under the automatic route for IT, pharma manufacturing (greenfield), and medical devices, requiring only post-facto RBI notification via FC-GPR
• The corporate tax rate for foreign companies dropped from 40% to 35% from April 2024, but the subsidiary structure at 22% effective rate remains significantly more tax-efficient
• The EU-India FTA (concluded January 2026) will further reduce trade barriers for Irish companies once ratified and implemented